These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2540748)

  • 1. The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
    Griffin K; Hong T; Levy JV
    Biochem Biophys Res Commun; 1989 Apr; 160(1):263-7. PubMed ID: 2540748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
    Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
    Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
    Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
    Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
    Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships and effects of platelet-activating factor antagonists in the hetrazepine series.
    Weber KH; Heuer H
    Int Arch Allergy Appl Immunol; 1989; 88(1-2):82-7. PubMed ID: 2540098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The specific binding of the platelet-activating factor (PAF) receptor antagonist WEB 2086 and the benzodiazepine flunitrazepam to rat hepatocytes.
    Svetlov SI; Barton JM; Olson MS
    Life Sci; 1996; 58(5):PL 81-6. PubMed ID: 8594301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet-activating factor (PAF) receptor antagonists inhibit arachidonic acid induced platelet aggregation in rabbit whole blood.
    Ammit AJ; O'Neill C
    Lipids; 1991 Dec; 26(12):1189-92. PubMed ID: 1668116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The thieno-triazolodiazepine WEB 2086 inhibits platelet aggregation and ATP release from porcine platelets induced by platelet activating factor (PAF).
    Griffin KJ; Levy JV
    Thromb Res; 1988 Jul; 51(2):219-23. PubMed ID: 3187959
    [No Abstract]   [Full Text] [Related]  

  • 11. Characterization of PAF receptors on human neutrophils using the specific antagonist, WEB 2086. Correlation between receptor binding and function.
    Dent G; Ukena D; Chanez P; Sybrecht G; Barnes P
    FEBS Lett; 1989 Feb; 244(2):365-8. PubMed ID: 2537761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of platelet-activating factor in hypotension and platelet activation induced by infusion of thrombolytic agents in rabbits.
    Montrucchio G; Alloatti G; Mariano F; Lupia E; Lucchina PG; Musso E; Emanuelli G; Camussi G
    Circ Res; 1993 Mar; 72(3):658-70. PubMed ID: 8381725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity.
    Casals-Stenzel J; Weber KH
    Br J Pharmacol; 1987 Jan; 90(1):139-46. PubMed ID: 2880622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages.
    Stewart AG; Dusting GJ
    Br J Pharmacol; 1988 Aug; 94(4):1225-33. PubMed ID: 2850058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes.
    Silva CL; Cruz HN; Violante FA; Cordeiro RS; Martins MA; Noël F
    Biochem Pharmacol; 1996 Jan; 51(2):193-6. PubMed ID: 8615889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of antiplatelet agents on platelet aggregation induced by platelet--activating factor (PAF) in human whole blood.
    Chan WP; Levy JV
    Prostaglandins; 1991 Oct; 42(4):337-42. PubMed ID: 1665568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine.
    da Silva MB; Herion F; Raskinet R; David JL; Gustin P; Dessy C; Lekeux P
    Zentralbl Veterinarmed A; 1996 Sep; 43(7):399-413. PubMed ID: 8921726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
    Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
    Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse.
    Foster AP; Lees P; Andrews MJ; Cunningham FM
    Equine Vet J; 1992 May; 24(3):203-7. PubMed ID: 1318830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.